JP2004502742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502742A5 JP2004502742A5 JP2002508475A JP2002508475A JP2004502742A5 JP 2004502742 A5 JP2004502742 A5 JP 2004502742A5 JP 2002508475 A JP2002508475 A JP 2002508475A JP 2002508475 A JP2002508475 A JP 2002508475A JP 2004502742 A5 JP2004502742 A5 JP 2004502742A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cell
- antibody
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 62
- 239000002246 antineoplastic agent Substances 0.000 description 29
- 229940127089 cytotoxic agent Drugs 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 21
- 239000012634 fragment Substances 0.000 description 16
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 12
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 12
- 229960004397 cyclophosphamide Drugs 0.000 description 12
- 101150013553 CD40 gene Proteins 0.000 description 11
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000004736 B-Cell Leukemia Diseases 0.000 description 10
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 9
- 108010024976 Asparaginase Proteins 0.000 description 9
- 208000003950 B-cell lymphoma Diseases 0.000 description 9
- 229940045799 anthracyclines and related substance Drugs 0.000 description 9
- 230000003325 follicular Effects 0.000 description 9
- 229960004618 prednisone Drugs 0.000 description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 229940100198 alkylating agent Drugs 0.000 description 6
- 239000002168 alkylating agent Substances 0.000 description 6
- 229960003272 asparaginase Drugs 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 6
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 6
- 229960004641 rituximab Drugs 0.000 description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
- 229960004528 vincristine Drugs 0.000 description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 6
- 108010029697 CD40 Ligand Proteins 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 3
- COURSARJQZMTEZ-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-propylbenzene-1,3-diol Chemical compound OC1=CC(CCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C COURSARJQZMTEZ-UHFFFAOYSA-N 0.000 description 3
- XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
- 108700034306 PROMACE-CytaBOM protocol Proteins 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- -1 anthracycline Chemical compound 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- JCYRRZITSZDHKN-WODMUGMNSA-N chlvpp protocol Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1.OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JCYRRZITSZDHKN-WODMUGMNSA-N 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- XMJCOTSQMHGIPF-SNSGICDFSA-N copp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 XMJCOTSQMHGIPF-SNSGICDFSA-N 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- YBGRCYCEEDOTDH-JYNQXTMKSA-N evap protocol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 YBGRCYCEEDOTDH-JYNQXTMKSA-N 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
- 229960001101 ifosfamide Drugs 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 210000001370 mediastinum Anatomy 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 229960000624 procarbazine Drugs 0.000 description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011347 external beam therapy Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 ＣＤ４０陽性悪性疾患の治療用医薬組成物であって、有効成分として、ＣＤ４０Ｌに結合してＣＤ４０／ＣＤ４０Ｌ相互作用またはＣＤ４０シグナリングを阻害する抗ＣＤ４０Ｌ抗体または抗体フラグメントを含有する医薬組成物。
【請求項２】 ＣＤ４０陽性悪性疾患がＢ細胞リンパ腫またはＢ細胞白血病である請求項１に記載の医薬組成物。
【請求項３】 Ｂ細胞リンパ腫がホジキン病または非ホジキンリンパ腫である請求項２に記載の医薬組成物。
【請求項４】 非ホジキンリンパ腫が低度、中等度及び高度である請求項３に記載の医薬組成物。
【請求項５】 非ホジキンリンパ腫が、小リンパ球性、濾胞性及び小型縦隔細胞優位、濾胞性及び小型縦隔及び大細胞混合型、濾胞性及び大細胞優位、びまん性小縦隔細胞、びまん性小細胞及び大細胞混合型、びまん性大細胞型、大細胞免疫芽球性、リンパ芽球性、小型非縦隔バーキット及び非バーキット型、エイズ関連リンパ腫、血管免疫芽球性リンパ節症、マントル細胞リンパ腫、及び単球性Ｂ細胞リンパ腫からなるサブタイプグループから選択される請求項３に記載の医薬組成物。
【請求項６】 Ｂ細胞白血病が慢性Ｂ細胞白血病、Ｂ細胞系の急性リンパ芽球性白血病、またはＢ細胞系リンパ球性白血病である請求項２に記載の医薬組成物。
【請求項７】 抗ＣＤ４０Ｌ抗体がＩＤＥＣ−１３１，３Ｅ４，２Ｈ５，２Ｈ８，４Ｄ９−８，４Ｄ９−９，２４−３１，２４−４３，８９−７６、８９−７９またはこれらの抗体のいずれか一つのフラグメントである請求項１に記載の医薬組成物。
【請求項８】 抗体または抗体フラグメントがキメラ、二重特異性、ヒトまたはヒト化である請求項１に記載の医薬組成物。
【請求項９】 抗体フラグメントがＦａｂ，Ｆａｂ’，ｓｃＦｖまたはＦ（ａｂ’）２である請求項１に記載の医薬組成物。
【請求項１０】 さらに第二の抗体またはそのフラグメント、一つまたはそれ以上の化学療法剤及び／または放射線療法を併用して同時にまたは連続して使用するための請求項１に記載の医薬組成物。
【請求項１１】 放射線療法が外部放射線治療であるかまたは放射標識抗体である請求項１０に記載の医薬組成物。
【請求項１２】 放射標識抗体が放射標識ＩＤＥＣ−１３１、ｒｉｔｕｘｉｍａｂ、Ｂ１、あるいは放射標識ＩＤＥＣ−１３１、ｒｉｔｕｘｉｍａｂまたはＢ１のフラグメントである請求項１１に記載の医薬組成物。
【請求項１３】 放射標識抗体が１２３Ｉ，１２５Ｉ，１３１Ｉ，１１１Ｉｎ，１３１Ｉｎ，３２Ｐ，６４Ｃｕ，６７Ｃｕ，２１１Ａｔ，１７７Ｌｕ，９０Ｙ，１８６Ｒｅ，２１２Ｐｂ，２１２Ｂｉ，４７Ｓｃ，１０５Ｒｈ，１０９Ｐｄ，１５３Ｓｍ，１８８Ｒｅ，１９９Ａｕ，２１１Ａｔ，及び２１３Ｂｉで放射標識されている請求項１１に記載の医薬組成物。
【請求項１４】 一つまたはそれ以上の化学療法剤がアルキル化剤、ビンカアルカロイド、プロカルバジン、メトトレキサートまたはプレドニゾンである請求項１０に記載の医薬組成物。
【請求項１５】 一つまたはそれ以上の化学療法剤がアルキル化剤、シクロホスファミド、クロランブシル、２−ＣＤＡ、２’−デオキシコフォルマイシン、フルダラビン、シトシンアラビノシド、シスプラチン、エトポシドまたはイフォスファミドである請求項１０に記載の医薬組成物。
【請求項１６】 化学療法剤の併用が、ＭＯＰＰ，ＡＢＶＤ，ＣｈｌＶＰＰ，ＣＡＢＳ，ＭＯＢＢ＋ＡＢＶＤ，ＭＯＰＰ＋ＡＢＶ，ＢＣＶＰＰ，ＶＡＢＣＤ，ＡＢＤＩＣ，ＣＢＶＤ，ＰＣＶＰ，ＣＥＰ，ＥＶＡ，ＭＯＰＬＡＣＥ，ＭＩＭＥ，ＭＩＮＥ，ＣＥＭ，ＭＴＸ−ＣＨＯＰ，ＥＶＡＰまたはＥＰＯＣＨのいずれか一つまたはそれ以上である請求項１０に記載の医薬組成物。
【請求項１７】 化学療法剤の併用が、ＣＶＰ，ＣＨＯＰ，Ｃ−ＭＯＰＰ，ＣＡＰ−ＢＯＰ，ｍ−ＢＡＣＯＤ，ＰｒｏＭＡＣＥ−ＭＯＰＰ，ＰｒｏＭＡＣＥ−ＣｙｔａＢＯＭ，ＭＡＣＯＰ−Ｂ，ＩＭＶＰ−１６，ＭＩＭＥ，ＤＨＡＰ，ＥＳＨＡＰ，ＣＥＰＰ（Ｂ）またはＣＡＭＰのいずれか一つまたはそれ以上である請求項１０に記載の医薬組成物。
【請求項１８】 一つまたはそれ以上の化学療法剤が、アントラサイクリン、シクロホスファミド、Ｌ−アスパラギナーゼまたはプリン同族体である請求項１０に記載の医薬組成物。
【請求項１９】 一つまたはそれ以上の化学療法剤が、ビンクリスチン、プレドニゾン、アントラサイクリン及びシクロホスファミドまたはアスパラギナーゼ；ビンクリスチン、プレドニゾン、アントラサイクリン、シクロホスファミド及びアスパラギナーゼ；ＣＨＯＰ；ＣＭＰ；ＣＶＰ；ＣＯＰまたはＣＡＰである請求項１０に記載の医薬組成物。
【請求項２０】 第二の抗体が抗−ＣＤ２０抗体である請求項１０に記載の医薬組成物。
【請求項２１】 抗−ＣＤ２０抗体が、ｒｉｔｕｘｉｍａｂ、Ｂ１あるいは、ｒｉｔｕｘｉｍａｂまたはＢ１のフラグメントである請求項２０に記載の医薬組成物。
【請求項２２】 ＣＤ４０陽性悪性疾患の治療用医薬組成物であって、有効成分として、ＣＤ４０−ＣＤ４０Ｌ相互作用またはＣＤ４０シグナリングを阻害する抗−ＣＤ２０抗体またはそのフラグメントと併用して、同時にあるいは連続して使用するための抗−ＣＤ４０Ｌ抗体またはそのフラグメントを含有する医薬組成物。
【請求項２３】 ＣＤ４０陽性悪性疾患がＢ細胞リンパ腫またはＢ細胞白血病である請求項２２に記載の医薬組成物。
【請求項２４】 ＣＤ４０陽性悪性疾患の治療用医薬組成物であって、有効成分として、（ｉ）化学療法剤または化学療法剤の併用、（ｉｉ）放射線療法、（ｉｉｉ）抗−ＣＤ２０抗体またはそのフラグメントおよび（ｉｖ）抗−ＣＤ４０抗体またはそのフラグメントと併用して同時にまたは連続して使用するためのＣＤ４０Ｌ拮抗剤を含有する医薬組成物。
【請求項２５】 放射線療法が外部放射線治療である請求項２４に記載の医薬組成物。
【請求項２６】 放射線療法が、１２３Ｉ，１２５Ｉ，１３１Ｉ，１１１Ｉｎ，１３１Ｉｎ，３２Ｐ，６４Ｃｕ，６７Ｃｕ，２１１Ａｔ，１７７Ｌｕ，９０Ｙ，１８６Ｒｅ，２１２Ｐｂ，２１２Ｂｉ，４７Ｓｃ，１０５Ｒｈ，１０９Ｐｄ，１５３Ｓｍ，１８８Ｒｅ，１９９Ａｕ，２１１Ａｔ，及び２１３Ｂｉで放射標識されている抗体である請求項２４に記載の医薬組成物。
【請求項２７】 ＣＤ４０陽性悪性疾患がＢ細胞白血病またはＢ細胞リンパ腫である請求項２４に記載の医薬組成物。
【請求項２８】 Ｂ細胞リンパ腫がホジキン病または非ホジキンリンパ腫である請求項２７に記載の医薬組成物。
【請求項２９】 非ホジキンリンパ腫が低度、中等度または高度である請求項２８に記載の医薬組成物。
【請求項３０】 非ホジキンリンパ腫が、小リンパ球性、濾胞性及び小型縦隔細胞優位、濾胞性及び小型縦隔及び大細胞混合型、濾胞性及び大細胞優位、びまん性小縦隔細胞、びまん性小細胞及び大細胞混合型、びまん性大細胞型、大細胞免疫芽球性、リンパ芽球性、小型非縦隔バーキット及び非バーキット型、エイズ関連リンパ腫、血管免疫芽球性リンパ節症、マントル細胞リンパ腫、及び単球性Ｂ細胞リンパ腫からなるサブタイプグループから選択される請求項２８に記載の医薬組成物。
【請求項３１】 Ｂ細胞白血病が慢性Ｂ細胞白血病、Ｂ細胞系の急性リンパ芽球性白血病、またはＢ細胞系の慢性リンパ球性白血病である請求項２７に記載の医薬組成物。
【請求項３２】 ＣＤ４０Ｌ拮抗剤が抗−ＣＤ４０Ｌ抗体またはそのフラグメントである請求項２４に記載の医薬組成物。
【請求項３３】 抗−ＣＤ４０Ｌ抗体がＩＤＥＣ−１３１またはそのフラグメントである請求項３２に記載の医薬組成物。
【請求項３４】 抗−ＣＤ４０Ｌ抗体フラグメントがＦａｂ，Ｆａｂ’，ｓｃＦｖまたはＦ（ａｂ’）２である請求項３２に記載の医薬組成物。
【請求項３５】 抗−ＣＤ２０抗体がｒｉｔｕｘｉｍａｂまたはそのフラグメントまたはＢ１またはそのフラグメントである請求項２４に記載の医薬組成物。
【請求項３６】 ホジキン病を治療するための化学療法剤または化学療法剤の併用が、アルキル化剤、ビンカアルカロイド、プロカルバジン、メトトレキサートまたはプレドニゾンのいずれか一つまたはそれ以上である請求項２８に記載の医薬組成物。
【請求項３７】 非ホジキンリンパ腫を治療するための化学療法剤または化学療法剤の併用が、アルキル化剤、シクロホスファミド、クロランブシル、２−ＣＤＡ、２’−デオキシコフォルマイシン、フルダラビン、シトシンアラビノシド、シスプラチン、エトポシドまたはイフォスファミドのいずれか一つまたはそれ以上である請求項２８に記載の医薬組成物。
【請求項３８】 ホジキン病を治療するための化学療法剤または化学療法剤の併用が、ＭＯＰＰ，ＡＢＶＤ，ＣｈｌＶＰＰ，ＣＡＢＳ，ＭＯＰＰ＋ＡＢＶＤ，ＭＯＰＰ＋ＡＢＶ，ＢＣＶＰＰ，ＶＡＢＣＤ，ＡＢＤＩＣ，ＣＢＶＤ，ＰＣＶＰ，ＣＥＰ，ＥＶＡ，ＭＯＰＬＡＣＥ，ＭＩＭＥ，ＭＩＮＥ，ＣＥＭ，ＭＴＸ−ＣＨＯＰ，ＥＶＡＰまたはＥＰＯＣＨのいずれか一つまたはそれ以上である請求項２８に記載の医薬組成物。
【請求項３９】 非ホジキンリンパ腫を治療するための化学療法剤または化学療法剤の併用が、ＣＶＰ，ＣＨＯＰ，Ｃ−ＭＯＰＰ，ＣＡＰ−ＢＯＰ，ｍ−ＢＡＣＯＤ，ＰｒｏＭＡＣＥ−ＭＯＰＰ，ＰｒｏＭＡＣＥ−ＣｙｔａＢＯＭ，ＭＡＣＯＰ−Ｂ，ＩＭＶＰ−１６，ＭＩＭＥ，ＤＨＡＰ，ＥＳＨＡＰ，ＣＥＰＰ（Ｂ），またはＣＡＭＰのいずれか一つまたはそれ以上である請求項２８に記載の医薬組成物。
【請求項４０】 Ｂ細胞白血病を治療するための化学療法剤または化学療法剤の併用が、アントラサイクリン、シクロホスファミド、Ｌ−アスパラギナーゼ、プリン同族体のいずれか一つまたはそれ以上である請求項２８に記載の医薬組成物。
【請求項４１】 Ｂ細胞白血病を治療するための化学療法剤または化学療法剤の併用が、ビンクリスチン、プレドニゾン、アントラサイクリン及びシクロホスファミドまたはアスパラギナーゼ；ビンクリスチン、プレドニゾン、アントラサイクリン、シクロホスファミド及びアスパラギナーゼ；ＣＨＯＰ；ＣＭＰ；ＣＶＰ；ＣＯＰまたはＣＡＰのいずれか一つまたはそれ以上である請求項２８に記載の医薬組成物。
【請求項４２】 ＣＤ４０陽性悪性疾患の治療用医薬組成物であって、有効成分として、
（ｉｉ）ＣＤ４０Ｌ，ＣＤ１９，ＣＤ２２またはＣＤ２０に結合する放射標識抗体、（ｉｉｉ）B細胞欠損抗体またはそのフラグメント、または（ｉｖ）化学療法剤または混合化学療法剤のいずれか一つまたはそれ以上と併用して同時にまたは連続して使用するための（ｉ）抗−ＣＤ４０Ｌ抗体またはその抗体フラグメントを含有する医薬組成物。
【請求項４３】 ＣＤ４０陽性悪性疾患がＢ細胞リンパ腫またはＢ細胞白血病である請求項４２に記載の医薬組成物。
【請求項４４】 Ｂ細胞白血病がホジキン病または非ホジキンリンパ腫である請求項４３に記載の医薬組成物。
【請求項４５】 放射標識抗体が放射標識ＩＤＥＣ−１３１、ＲＩＴＵＸＡＮＴＭ、またはＢ１である請求項４２に記載の医薬組成物。
【請求項４６】 放射標識抗体が１２３Ｉ，１２５Ｉ，１３１Ｉ，１１１Ｉｎ，１３１Ｉｎ，３２Ｐ，６４Ｃｕ，６７Ｃｕ，２１１Ａｔ，１７７Ｌｕ，９０Ｙ，１８６Ｒｅ，２１２Ｐｂ，２１２Ｂｉ，４７Ｓｃ，１０５Ｒｈ，１０９Ｐｄ，１５３Ｓｍ，１８８Ｒｅ，１９９Ａｕ，２１１Ａｔ，及び２１３Ｂｉで放射標識されている請求項４５に記載の医薬組成物。
【請求項４７】 非ホジキンリンパ腫が低度、中等度または高度である請求項４４に記載の医薬組成物。
【請求項４８】 非ホジキンリンパ腫が、小リンパ球性、濾胞性及び小型縦隔細胞優位、濾胞性及び小型縦隔及び大細胞混合型、濾胞性及び大細胞優位、びまん性小縦隔細胞、びまん性小細胞及び大細胞混合型、びまん性大細胞型、大細胞免疫芽球性、リンパ芽球性、小型非縦隔バーキット及び非バーキット型、エイズ関連リンパ腫、血管免疫芽球性リンパ節症、マントル細胞リンパ腫、及び単球性Ｂ細胞リンパ腫からなるＮＨＬサブタイプグループから選択される請求項４４に記載の医薬組成物。
【請求項４９】 抗−ＣＤ４０Ｌ抗体がＩＤＥＣ−１３１またはそのフラグメントである請求項４２に記載の医薬組成物。
【請求項５０】 Ｂ細胞欠損抗体が、抗−ＣＤ２０抗体またはそのフラグメントまたはＢ１またはそのフラグメントである請求項４２に記載の医薬組成物。
【請求項５１】 化学療法剤が、アルキル化剤、ビンカアルカロイド、プロカルバジン、メトトレキサートまたはプレドニゾンのいずれか一つまたはそれ以上である請求項４２に記載の医薬組成物。
【請求項５２】 化学療法剤が、アルキル化剤、シクロホスファミド、クロランブシル、２−ＣＤＡ、２’−デオキシコフォルマイシン、フルダラビン、シトシンアラビノシド、シスプラチン、エトポシドまたはイフォスファミドのいずれか一つまたはそれ以上である請求項４２に記載の医薬組成物。
【請求項５３】 化学療法剤の併用が、ＭＯＰＰ，ＡＢＶＤ，ＣｈｌＶＰＰ，ＣＡＢＳ，ＭＯＰＰ＋ＡＢＶＤ，ＭＯＰＰ＋ＡＢＶ，ＢＣＶＰＰ，ＶＡＢＣＤ，ＡＢＤＩＣ，ＣＢＶＤ，ＰＣＶＰ，ＣＥＰ，ＥＶＡ，ＭＯＰＬＡＣＥ，ＭＩＭＥ，ＭＩＮＥ，ＣＥＭ，ＭＴＸ−ＣＨＯＰ，ＥＶＡＰまたはＥＰＯＣＨである請求項４２に記載の医薬組成物。
【請求項５４】 化学療法剤の併用が、ＣＶＰ，ＣＨＯＰ，Ｃ−ＭＯＰＰ，ＣＡＰ−ＢＯＰ，ｍ−ＢＡＣＯＤ，ＰｒｏＭＡＣＥ−ＭＯＰＰ，ＰｒｏＭＡＣＥ−ＣｙｔａＢＯＭ，ＭＡＣＯＰ−Ｂ，ＩＭＶＰ−１６，ＭＩＭＥ，ＤＨＡＰ，ＥＳＨＡＰ，ＣＥＰＰ（Ｂ），またはＣＡＭＰである請求項４２に記載の医薬組成物。
【請求項５５】 化学療法剤が、アントラサイクリン、シクロホスファミド、Ｌ−アスパラギナーゼ、プリン同族体である請求項４２に記載の医薬組成物。
【請求項５６】 化学療法剤の併用が、ビンクリスチン、プレドニゾン、アントラサイクリン及びシクロホスファミドまたはアスパラギナーゼ；ビンクリスチン、プレドニゾン、アントラサイクリン、シクロホスファミド及びアスパラギナーゼ；ＣＨＯＰ；ＣＭＰ；ＣＶＰ；ＣＯＰまたはＣＡＰ、である請求項４２に記載の医薬組成物。
[Claims]
1. A pharmaceutical composition for treating a CD40-positive malignant disease, which comprises, as an active ingredient, an anti-CD40L antibody or an antibody fragment that binds to CD40L and inhibits CD40 / CD40L interaction or CD40 signaling. object.
2. The pharmaceutical composition according to claim 1, wherein the CD40-positive malignant disease is B-cell lymphoma or B-cell leukemia.
3. The pharmaceutical composition according to claim 2, wherein the B cell lymphoma is Hodgkin's disease or non-Hodgkin's lymphoma.
4. The pharmaceutical composition according to claim 3, wherein the non-Hodgkin's lymphoma is low, moderate and advanced.
5. The non-Hodgkin's lymphoma is small lymphocytic, follicular and small mediastinal cell dominant, follicular and small mediastinal and large cell mixed type, follicular and large cell dominant, diffuse small mediastinal cell, Diffuse mixed small and large cells, diffuse large cell, large cell immunoblastic, lymphoblastic, small non-mediastinum Burkitt and non-burkitt, AIDS-related lymphoma, vascular immunoblastic lymphoid 4. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is selected from the subtype group consisting of nodal disease, mantle cell lymphoma, and monocytic B cell lymphoma.
6. The pharmaceutical composition according to claim 2, wherein the B-cell leukemia is chronic B-cell leukemia, B-cell acute lymphoblastic leukemia, or B-cell lymphocytic leukemia.
7. The anti-CD40L antibody is IDEC-131, 3E4, 2H5, 2H8, 4D9-8, 4D9-9, 24-31, 24-43, 89-76, 89-79, or any one of these antibodies. 2. The pharmaceutical composition according to claim 1, which is one fragment.
8. The pharmaceutical composition according to claim 1, wherein the antibody or antibody fragment is chimeric, bispecific, human or humanized.
9. The pharmaceutical composition according to claim 1, wherein the antibody fragment is Fab, Fab ', scFv or F (ab') 2 .
10. The pharmaceutical composition according to claim 1, further for simultaneous or sequential use of a second antibody or fragment thereof, one or more chemotherapeutic agents and / or radiation therapy. .
11. The pharmaceutical composition according to claim 10, wherein the radiation therapy is external radiation therapy or a radiolabeled antibody.
12. The pharmaceutical composition according to claim 11, wherein the radiolabeled antibody is radiolabeled IDEC-131, rituximab, B1, or a fragment of radiolabeled IDEC-131, rituximab or B1.
13. The radiolabeled antibody is 123 I, 125 I, 131 I, 111 In, 131 In, 32 P, 64 Cu, 67 Cu, 211 At, 177 Lu, 90 Y, 186 Re, 212 Pb, 212 Bi. The pharmaceutical composition according to claim 11, which is radiolabeled with, 47 Sc, 105 Rh, 109 Pd, 153 Sm, 188 Re, 199 Au, 211 At, and 213 Bi.
14. The pharmaceutical composition according to claim 10, wherein the one or more chemotherapeutic agents is an alkylating agent, vinca alkaloid, procarbazine, methotrexate or prednisone.
15. The method of claim 15, wherein the one or more chemotherapeutic agents is an alkylating agent, cyclophosphamide, chlorambucil, 2-CDA, 2'-deoxycoformycin, fludarabine, cytosine arabinoside, cisplatin, etoposide or ifosfamide. The pharmaceutical composition according to claim 10, which is
16. The combination use of a chemotherapeutic agent includes MOPP, ABVD, ChlVPP, CABS, MOBB + ABVD, MOPP + ABV, BCVPP, VABCD, ABDIC, CBVD, PCVP, CEP, EVA, MOPLACE, MINE, MINE, CEM, MTX-CHOP. 11. The pharmaceutical composition according to claim 10, which is one or more of EVAP or EPOCH.
17. The combination use of a chemotherapeutic agent is CVP, CHOP, C-MOPP, CAP-BOP, m-BACODE, ProMACE-MOPP, ProMACE-CytaBOM, MACOP-B, IMVP-16, MIME, DHAP, ESHAP, The pharmaceutical composition according to claim 10, which is one or more of CEPP (B) and CAMP.
18. The pharmaceutical composition according to claim 10, wherein the one or more chemotherapeutic agents is an anthracycline, cyclophosphamide, L-asparaginase or a purine homolog.
19. The one or more chemotherapeutic agents are vincristine, prednisone, anthracycline and cyclophosphamide or asparaginase; vincristine, prednisone, anthracycline, cyclophosphamide and asparaginase; CHOP; CMP; CVP; The pharmaceutical composition according to claim 10, which is COP or CAP.
20. The pharmaceutical composition according to claim 10, wherein the second antibody is an anti-CD20 antibody.
21. The pharmaceutical composition according to claim 20, wherein the anti-CD20 antibody is rituximab, B1, or a fragment of rituximab or B1.
22. A pharmaceutical composition for treating a CD40-positive malignant disease, which is used in combination with an anti-CD20 antibody or a fragment thereof that inhibits CD40-CD40L interaction or CD40 signaling, as an active ingredient, simultaneously or sequentially. A pharmaceutical composition comprising an anti-CD40L antibody or a fragment thereof for use in a pharmaceutical composition.
23. The pharmaceutical composition according to claim 22, wherein the CD40-positive malignant disease is B-cell lymphoma or B-cell leukemia.
24. A pharmaceutical composition for treating a CD40-positive malignant disease, wherein the active ingredient is (i) a chemotherapeutic agent or a combination of chemotherapeutic agents, (ii) radiation therapy, (iii) an anti-CD20 antibody or A pharmaceutical composition comprising a fragment thereof and (iv) a CD40L antagonist for simultaneous or sequential use in combination with an anti-CD40 antibody or fragment thereof.
25. The pharmaceutical composition according to claim 24, wherein the radiation therapy is external radiation therapy.
26. Radiotherapy is performed using 123 I, 125 I, 131 I, 111 In, 131 In, 32 P, 64 Cu, 67 Cu, 211 At, 177 Lu, 90 Y, 186 Re, 212 Pb, 212 Bi. 25. The pharmaceutical composition according to claim 24, which is an antibody radiolabeled with, 47 Sc, 105 Rh, 109 Pd, 153 Sm, 188 Re, 199 Au, 211 At, and 213 Bi.
27. The pharmaceutical composition according to claim 24, wherein the CD40-positive malignant disease is B-cell leukemia or B-cell lymphoma.
28. The pharmaceutical composition according to claim 27, wherein the B cell lymphoma is Hodgkin's disease or non-Hodgkin's lymphoma.
29. The pharmaceutical composition according to claim 28, wherein the non-Hodgkin's lymphoma is low, moderate or advanced.
30. The non-Hodgkin's lymphoma is small lymphocytic, follicular and small mediastinal cell dominant, mixed follicular and small mediastinal and large cell type, follicular and large cell dominant, diffuse small mediastinal cell, Diffuse mixed small and large cells, diffuse large cell, large cell immunoblastic, lymphoblastic, small non-mediastinum Burkitt and non-burkitt, AIDS-related lymphoma, vascular immunoblastic lymphoid 29. The pharmaceutical composition according to claim 28, wherein the pharmaceutical composition is selected from the subtype group consisting of nodal disease, mantle cell lymphoma, and monocytic B cell lymphoma.
31. The pharmaceutical composition according to claim 27, wherein the B-cell leukemia is chronic B-cell leukemia, B-cell acute lymphoblastic leukemia, or B-cell chronic lymphocytic leukemia.
32. The pharmaceutical composition according to claim 24, wherein the CD40L antagonist is an anti-CD40L antibody or a fragment thereof.
33. The pharmaceutical composition according to claim 32, wherein the anti-CD40L antibody is IDEC-131 or a fragment thereof.
34. The pharmaceutical composition according to claim 32, wherein the anti-CD40L antibody fragment is Fab, Fab ', scFv or F (ab') 2 .
35. The pharmaceutical composition according to claim 24, wherein the anti-CD20 antibody is rituximab or a fragment thereof or B1 or a fragment thereof.
36. The chemotherapeutic agent or combination of chemotherapeutic agents for treating Hodgkin's disease is any one or more of an alkylating agent, vinca alkaloid, procarbazine, methotrexate or prednisone. Pharmaceutical composition.
37. A chemotherapeutic agent or combination of chemotherapeutic agents for treating non-Hodgkin's lymphoma, wherein the agent is an alkylating agent, cyclophosphamide, chlorambucil, 2-CDA, 2'-deoxycoformycin, fludarabine, cytosine. 29. The pharmaceutical composition according to claim 28, which is one or more of arabinoside, cisplatin, etoposide, and ifosfamide.
38. A chemotherapeutic agent or combination of chemotherapeutic agents for treating Hodgkin's disease comprises MOPP, ABVD, ChlVPP, CABS, MOPP + ABVD, MOPP + ABV, BCVPP, VABCD, ABDIC, CBVD, PCVP, CEP, EVA, MOPLACE. 29. The pharmaceutical composition according to claim 28, wherein the composition is any one or more of, MIM, MINE, CEM, MTX-CHOP, EVAP, and EPOCH.
39. A chemotherapeutic agent or combination of chemotherapeutic agents for treating non-Hodgkin's lymphoma, wherein CVP, CHOP, C-MOPP, CAP-BOP, m-BACODE, ProMACE-MOPP, ProMACE-CytaBOM, MACOP- 29. The pharmaceutical composition according to claim 28, which is any one or more of B, IMVP-16, MIME, DHAP, ESHAP, CEPP (B), or CAMP.
40. The chemotherapeutic agent or combination of chemotherapeutic agents for treating B-cell leukemia is any one or more of anthracycline, cyclophosphamide, L-asparaginase, and a purine homolog. Item 29. The pharmaceutical composition according to Item 28.
41. A chemotherapeutic agent or combination of chemotherapeutic agents for treating B-cell leukemia, comprising: vincristine, prednisone, anthracycline and cyclophosphamide or asparaginase; vincristine, prednisone, anthracycline, cyclophosphamide and 29. The pharmaceutical composition according to claim 28, which is one or more of asparaginase; CHOP; CMP; CVP; COP or CAP.
42. A pharmaceutical composition for treating a CD40-positive malignant disease, which comprises as an active ingredient:
(Ii) a radiolabeled antibody that binds to CD40L, CD19, CD22 or CD20, (iii) a B-cell deficient antibody or a fragment thereof, or (iv) a chemotherapeutic agent or a combination chemotherapeutic agent. A pharmaceutical composition comprising (i) an anti-CD40L antibody or an antibody fragment thereof for simultaneous or sequential use.
43. The pharmaceutical composition according to claim 42, wherein the CD40-positive malignant disease is B-cell lymphoma or B-cell leukemia.
44. The pharmaceutical composition according to claim 43, wherein the B cell leukemia is Hodgkin's disease or non-Hodgkin's lymphoma.
45. The pharmaceutical composition according to claim 42, wherein the radiolabeled antibody is radiolabeled IDEC-131, RITUXAN ™ , or B1.
46. The radiolabeled antibody is 123 I, 125 I, 131 I, 111 In, 131 In, 32 P, 64 Cu, 67 Cu, 211 At, 177 Lu, 90 Y, 186 Re, 212 Pb, 212 Bi. 46. The pharmaceutical composition of claim 45, which is radiolabeled with, 47 Sc, 105 Rh, 109 Pd, 153 Sm, 188 Re, 199 Au, 211 At, and 213 Bi.
47. The pharmaceutical composition according to claim 44, wherein the non-Hodgkin's lymphoma is low, moderate or advanced.
48. The non-Hodgkin's lymphoma is small lymphocytic, follicular and small mediastinal cell dominant, follicular and small mediastinal and large cell mixed type, follicular and large cell dominant, diffuse small mediastinal cell, Diffuse mixed small and large cells, diffuse large cell, large cell immunoblastic, lymphoblastic, small non-mediastinum Burkitt and non-burkitt, AIDS-related lymphoma, vascular immunoblastic lymphoid 45. The pharmaceutical composition according to claim 44, wherein the composition is selected from the NHL subtype group consisting of nodal disease, mantle cell lymphoma, and monocytic B cell lymphoma.
49. The pharmaceutical composition according to claim 42, wherein the anti-CD40L antibody is IDEC-131 or a fragment thereof.
50. The pharmaceutical composition according to claim 42, wherein the B cell deficient antibody is an anti-CD20 antibody or a fragment thereof or B1 or a fragment thereof.
51. The pharmaceutical composition according to claim 42, wherein the chemotherapeutic agent is any one or more of an alkylating agent, vinca alkaloid, procarbazine, methotrexate and prednisone.
52. The chemotherapeutic agent is any one of an alkylating agent, cyclophosphamide, chlorambucil, 2-CDA, 2′-deoxycoformycin, fludarabine, cytosine arabinoside, cisplatin, etoposide, or ifosfamide. 43. The pharmaceutical composition according to claim 42, which is or more.
53. A combination of a chemotherapeutic agent comprising MOPP, ABVD, ChlVPP, CABS, MOPP + ABVD, MOPP + ABV, BCVPP, VABCD, ABDIC, CBVD, PCVP, CEP, EVA, MOPLACE, MIME, MINE, CEM, MTX-CHOP. 43. The pharmaceutical composition according to claim 42, which is EVAP or EPOCH.
54. The combination of a chemotherapeutic agent, wherein CVP, CHOP, C-MOPP, CAP-BOP, m-BACODE, ProMACE-MOPP, ProMACE-CytaBOM, MACOP-B, IMVP-16, MIME, DHAP, ESHAP, 43. The pharmaceutical composition according to claim 42, which is CEPP (B) or CAMP.
55. The pharmaceutical composition according to claim 42, wherein the chemotherapeutic agent is an anthracycline, cyclophosphamide, L-asparaginase, a purine homolog.
56. A combination of a chemotherapeutic agent comprising vincristine, prednisone, anthracycline and cyclophosphamide or asparaginase; vincristine, prednisone, anthracycline, cyclophosphamide and asparaginase; CHOP; CMP; CVP; COP or CAP; 43. The pharmaceutical composition according to claim 42, wherein
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21770600P | 2000-07-12 | 2000-07-12 | |
| US09/772,938 US20020006404A1 (en) | 1999-11-08 | 2001-01-31 | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| PCT/US2001/015677 WO2002004021A1 (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502742A JP2004502742A (en) | 2004-01-29 |
| JP2004502742A5 true JP2004502742A5 (en) | 2008-07-03 |
Family
ID=26912176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002508475A Abandoned JP2004502742A (en) | 2000-07-12 | 2001-05-16 | B-cell malignant disease treatment-related application using antibodies that kill B cells and immunomodulatory antibodies in combination |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1305045A1 (en) |
| JP (1) | JP2004502742A (en) |
| KR (2) | KR20080039547A (en) |
| CN (1) | CN1446104A (en) |
| AU (2) | AU2001264612C1 (en) |
| CA (1) | CA2415100A1 (en) |
| IL (1) | IL153764A0 (en) |
| MX (1) | MXPA03000306A (en) |
| NO (1) | NO20030128L (en) |
| SG (1) | SG136804A1 (en) |
| WO (1) | WO2002004021A1 (en) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011279A (en) | 1999-05-07 | 2002-07-02 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers. |
| EP1299128A2 (en) * | 2000-06-20 | 2003-04-09 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| JP2004508420A (en) * | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Combination therapy for treating autoimmune diseases using B cell depleting antibody / immunomodulatory antibody combination |
| RU2408606C2 (en) | 2000-10-20 | 2011-01-10 | Тугаи Сейяку Кабусики Кайся | Compound-agonist of thrombopoietin |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2436180C (en) * | 2001-01-31 | 2011-11-08 | Idec Pharmaceutical Corporation | Immunoregulatory antibodies and uses thereof |
| JP4679035B2 (en) * | 2001-04-02 | 2011-04-27 | ジェネンテック， インコーポレイテッド | Combination therapy |
| AU2003210266A1 (en) * | 2002-02-14 | 2003-09-04 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| CA2502552C (en) | 2002-10-17 | 2019-02-12 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| JP2004279086A (en) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | Radiation image conversion panel and method for manufacturing it |
| EP1609803A4 (en) * | 2003-03-31 | 2006-05-24 | Chugai Pharmaceutical Co Ltd | Modified antibody against cd22 and utilization thereof |
| MXPA05010778A (en) | 2003-04-09 | 2005-12-12 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor. |
| MXPA05013117A (en) | 2003-06-05 | 2006-03-17 | Genentech Inc | Combination therapy for b cell disorders. |
| KR20120125634A (en) | 2003-10-16 | 2012-11-16 | 마이크로메트 에이지 | Multispecific deimmunized cd3-binders |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| EP1844815B1 (en) * | 2003-11-04 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| HUE038955T2 (en) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| AR049200A1 (en) | 2004-06-04 | 2006-07-05 | Genentech Inc | METHOD TO TREAT MULTIPLE SCLEROSIS WITH A COMPOSITION CONTAINING A CD20 ANTIBODY |
| CA2597924C (en) * | 2005-02-15 | 2018-10-02 | Duke University | Anti-cd19 antibodies and uses in oncology |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| JP5057967B2 (en) | 2005-03-31 | 2012-10-24 | 中外製薬株式会社 | sc (Fv) 2 structural isomer |
| JP5129122B2 (en) * | 2005-04-26 | 2013-01-23 | トリオン ファーマ ゲーエムベーハー | Combination of antibodies and glucocorticoids for cancer treatment |
| JP5085322B2 (en) | 2005-06-10 | 2012-11-28 | 中外製薬株式会社 | Pharmaceutical composition containing sc (Fv) 2 |
| KR101367544B1 (en) | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | Stabilizer for protein preparation comprising meglumine and use thereof |
| RS54088B1 (en) | 2005-07-25 | 2015-10-30 | Emergent Products Development Seattle Llc | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| CA2616386A1 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals Inc. | Single dose use of cd20-specific binding molecules |
| WO2007019865A2 (en) | 2005-08-18 | 2007-02-22 | Genmab A/S | Therapy with cd4 binding peptides and radiation |
| AU2006308606C1 (en) | 2005-11-01 | 2013-07-25 | Novartis Ag | Uses of anti-CD40 antibodies |
| AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
| EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
| KR101571027B1 (en) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | Single-chain multivalent binding proteins with effector function |
| KR101643514B1 (en) | 2007-07-09 | 2016-07-27 | 제넨테크, 인크. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| EP2233149B1 (en) | 2007-10-16 | 2016-02-10 | ZymoGenetics, Inc. | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| NZ588671A (en) * | 2008-04-11 | 2012-11-30 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| AR073295A1 (en) | 2008-09-16 | 2010-10-28 | Genentech Inc | METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE. |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| KR20180010324A (en) | 2009-08-11 | 2018-01-30 | 제넨테크, 인크. | Production of proteins in glutamine-free cell culture media |
| MX341687B (en) | 2010-02-10 | 2016-08-30 | Immunogen Inc | Cd20 antibodies and uses thereof. |
| CN102971012B (en) | 2010-03-12 | 2016-05-04 | 伊缪诺金公司 | CD37 binding molecule and immunoconjugates thereof |
| AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
| WO2015046467A1 (en) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | Method for producing polypeptide heteromultimer |
| MA41459A (en) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
| JP6979877B2 (en) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル， エス． アー． | Combination of anti-CD37 immunoconjugate and anti-CD20 antibody |
| PE20221007A1 (en) | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY |
| MX2018002467A (en) | 2015-08-28 | 2018-06-15 | Debiopharm Int Sa | Antibodies and assays for detection of cd37. |
| CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| CN114031689A (en) | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use |
| AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
| CN108473555B (en) | 2015-11-02 | 2022-10-25 | 生物蛋白有限公司 | Conditionally active polypeptides |
| BR112018009312A8 (en) | 2015-12-28 | 2019-02-26 | Chugai Pharmaceutical Co Ltd | method for promoting purification efficiency of fc region-containing polypeptide |
| EP3535297B1 (en) | 2016-11-02 | 2022-08-10 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| AU2018271915A1 (en) | 2017-05-24 | 2019-11-28 | Als Therapy Development Institute | Therapeutic anti-CD40 ligand antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0669836T3 (en) * | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
-
2001
- 2001-05-16 SG SG200500152-4A patent/SG136804A1/en unknown
- 2001-05-16 CA CA002415100A patent/CA2415100A1/en not_active Abandoned
- 2001-05-16 EP EP01939050A patent/EP1305045A1/en not_active Withdrawn
- 2001-05-16 KR KR1020087009742A patent/KR20080039547A/en not_active Application Discontinuation
- 2001-05-16 MX MXPA03000306A patent/MXPA03000306A/en not_active Application Discontinuation
- 2001-05-16 WO PCT/US2001/015677 patent/WO2002004021A1/en active IP Right Grant
- 2001-05-16 KR KR10-2003-7000429A patent/KR20030031957A/en not_active Application Discontinuation
- 2001-05-16 IL IL15376401A patent/IL153764A0/en unknown
- 2001-05-16 AU AU2001264612A patent/AU2001264612C1/en not_active Ceased
- 2001-05-16 AU AU6461201A patent/AU6461201A/en active Pending
- 2001-05-16 CN CN01814063A patent/CN1446104A/en active Pending
- 2001-05-16 JP JP2002508475A patent/JP2004502742A/en not_active Abandoned
-
2003
- 2003-01-10 NO NO20030128A patent/NO20030128L/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004502742A5 (en) | ||
| JP2003513937A5 (en) | ||
| RU2002115285A (en) | TREATMENT OF B-CELL MALIGNANT TUMORS USING ANTIBODIES AGAINST CD40L IN COMBINATION WITH ANTIBODIES AGAINST CD20 AND / OR CHEMOTHERAPY AND RADIOTHERAPY | |
| Rastetter et al. | Rituximab: expanding role in therapy for lymphomas and autoimmune diseases | |
| AU2001270134B2 (en) | Methods for enhancing antibody-induced cell lysis and treating cancer | |
| CA2350058C (en) | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody | |
| JP2005503109A5 (en) | ||
| AU784174B2 (en) | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy | |
| RU2306952C2 (en) | Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies | |
| JP2003506414A5 (en) | ||
| JP2003501401A5 (en) | ||
| JP2017515802A5 (en) | ||
| Hainsworth | Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis | |
| JP2007513073A5 (en) | ||
| CA2436180A1 (en) | Immunoregulatory antibodies and uses thereof | |
| JP2005503999A5 (en) | ||
| WO2003057140A3 (en) | Composition and methods for treatment of neurological disorders | |
| CN102439071A (en) | Gaba-linked anthracycline-lipid conjugates | |
| Kim et al. | Results of CHOP-Bleo/CMED Alternating Chemotherapy for Aggressive Non-Hodgkin's Lymphoma | |
| Smith | Antibodies and hematologic malignancies | |
| JPWO2020043878A5 (en) | ||
| Lin et al. | Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia | |
| Niitsu | Pharmacotherapy of B-cell non-Hodgkin Lymphoma: Focus on Rituximab. |